Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

被引：0
|
作者：
Roe, MT [1 ]
Sapp, SK [1 ]
Lincoff, AM [1 ]
机构：
[1] Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA
来源：
CLEVELAND CLINIC JOURNAL OF MEDICINE | 2000年 / 67卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glycoprotein (GP) IIb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.
引用
收藏
页码：131 / 140
页数：12
相关论文
共 50 条
  • [21] Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
    Iannetta, Loredana
    Puddu, Paolo Emilio
    Cuturello, Domenico
    Saladini, Angela
    Pellicano, Mariano
    Schiariti, Michele
    CARDIOLOGY RESEARCH, 2013, 4 (01) : 1 - 7
  • [22] The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes
    Koller, CF
    HEART & LUNG, 2001, 30 (05): : 321 - 331
  • [23] Glycoprotein IIb/IIIa inhibitors and acute coronary syndromes: summary report of the full submission to NICE, and beyond
    Manoharan, G
    Adgey, AAJ
    HEART, 2001, 86 (03) : 259 - 261
  • [24] Integrating GP IIb/IIIa inhibitors in the management of acute coronary syndromes
    Simoons, ML
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2000, 2 (0C) : C22 - C25
  • [25] Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes
    VandeWerf, F
    THROMBOSIS AND HAEMOSTASIS, 1997, 78 (01) : 210 - 213
  • [26] Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
    Topol, E
    Califf, R
    Simoons, M
    Diaz, R
    Paolasso, E
    Klein, W
    Boland, J
    DeBacker, G
    Armstrong, P
    Corbalan, R
    Isaza, D
    Widimsky, P
    Urrutia, C
    Luomanmäki, K
    Vahanian, A
    Karsch, K
    Cokkinos, D
    Karatasakis, G
    Toutouzas, P
    Rodas, M
    Keltai, M
    Chierchia, S
    Silva, E
    Erikssen, J
    Ruzyllo, W
    Stepinska, J
    Ribeiro, VD
    Fernandez-Ortiz, A
    Macaya, C
    Goy, J
    Deckers, J
    Skene, A
    Wilcox, R
    Guerci, A
    Harrington, R
    Hochman, J
    Holmes, D
    Kleiman, N
    Kopecky, S
    Lee, K
    Lincoff, A
    Ohman, E
    Pepine, C
    Isea, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07): : 436 - 443
  • [27] A symposium: Safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes
    Tcheng, JE
    AMERICAN HEART JOURNAL, 1999, 138 (04) : S261 - S262
  • [28] Non-ST-elevation acute coronary syndromes management: a fresh look at glycoprotein IIb/IIIa inhibitors
    Cavallini, C
    Chirillo, F
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2005, 7 (0K) : K10 - K14
  • [29] Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes - Questions, answers, and more questions
    Mahaffey, Kenneth W.
    Harrington, Robert A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (06): : 636 - 639
  • [30] Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: Initiate treatment early or wait for the catheterization laboratory?
    Harnick D.J.
    Vorchheimer D.A.
    Current Cardiology Reports, 2001, 3 (5) : 355 - 361
12345